A Phase 3 interventional study of HRS9531 Injection and Semaglutide Injection in Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ribupatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. ribupatide · Diabetes Mellitus, Type 2.
Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 6 that started in 2024, is one of 3 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 11 studies testing ribupatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2024.
This study's enrollment of 884 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 72 across the 11 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
This study is registered under Fujian Shengdi Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.
81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd.: 8 open now, 11 under way, 4 of them phase 3. Of 50 finished, 0 (0%) have results posted.
Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one has the largest enrollment, is one of 15 that started in 2024, is one of 18 in phase 3, and was the 63rd registered.
Jiangsu HengRui Medicine Co., Ltd.’s Diabetes Mellitus, Type 2 studies by the year they started, since 2011.
1 of the studies testing ribupatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 81 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HRS953-low dose
Drug: HRS9531 Injection
HRS9531-high dose
Drug: HRS9531 Injection
Semaglutide-1mg
Drug: Semaglutide Injection
HRS9531 injected subcutaneously once weekly.
Semaglutide injected subcutaneously once weekly.
Change in HbA1c
Change from baseline in Glycosylated Haemoglobin after 36 weeks of treatment.
Time frame: Week 0 to Week 36
Change in body weight
Change from baseline in body weight after 36 weeks of treatment.
Time frame: Week 0 to Week 36
Proportion of Subjects with HbA1c≤6.5%
Proportion of subjects with HbA1c≤6.5% after 36 weeks of treatment.
Time frame: Week 0 to Week 36
Proportion of Subjects with HbA1c<7%
Proportion of subjects with HbA1c\<7% after 36 weeks of treatment.
Time frame: Week 0 to Week 36
Change in FPG (fasting plasma glucose)
Change from baseline in FPG after 36 weeks of treatment.
Time frame: Week 0 to Week 36
Change in FPG (fasting plasma glucose)
Change from baseline in FPG after 52 weeks of treatment.
Time frame: Week 0 to Week 52
7-points SMPG profiles
Fluctuation of 7-point SMPG. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner,120 minutes after start of dinner, before bedtime.
Time frame: Week 0 to Week 36
Incidence and severity of adverse events
Severity (mild, moderate and severe) is assessed by investigator.
Time frame: Week 0 to Week 52+4 weeks follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Jul 2026, 20 months.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribupatide
Fujian Shengdi Pharmaceutical Co., Ltd. →